Compare AbbVie Inc (ABBV) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Rivian Automotive, Inc. — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Rivian Automotive, Inc. trades at $16.59 (market cap $22.44B). The key difference: AbbVie Inc is far larger — about 20× Rivian Automotive, Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | RIVN | |
|---|---|---|
Market Cap | $449.91B | $22.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $22.45 |
52-Week Low | $184.85 | $11.64 |
Enterprise Value | $513.38B | $24.19B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Rivian (RIVN) trades at $16.49, down 11.49% amid a 75 million share offering announced July 7, 2026, raising dilution concerns despite recent quarterly EPS beats. The stock shows a bullish technical signal with moving averages supporting upside, but RSI indicates overbought conditions. Revenue grew to $5.39B in 2025, yet net losses persist at -$3.65B, with cash flow negative but improving. Analyst consensus is mixed with a $21.29 price target.
Outlook remains challenged by high cash burn and dilution risks, but cost reductions and DOE loan potential offer long-term growth avenues. Investors face volatility from EV competition and execution hurdles, though institutional buy ratings suggest cautious optimism for profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
